At @Amgen, we’re united in the fight against cancer. 💙 ⬇️Our team members share how progress for patients makes them feel. #UnitedByUnique #WorldCancerDay 🌍

Each cancer journey is unique, but we’re united in the fight for a brighter future. This #WorldCancerDay, we stand with @uicc to advocate for the unique experiences and needs of those affected by cancer. #UnitedbyUnique 🔗

Hope begins with care that sees the individual. This #WorldCancerDay 🌍 @Amgen’s patient advocacy allies share how hope & collaboration inspire action and healing. #UnitedByUnique

🔍Meet #DLL3 – a protein that’s highly prevalent in small cell lung cancer. At @Amgen, we’re targeting DLL3 to provide new options for patients battling this aggressive disease.

💡How can we harness a patient’s own immune system to fight cancer? @Amgen’s @judd_englert & @IFenChang1 share the cutting-edge innovation behind our Bispecific T-cell Engager (BiTE®) technology ⬇️

🧬#GastricCancer biomarkers can help personalize care & potentially deliver better treatment outcomes. Discover strategies to support testing in your practice ⬇️ #ASCOGI25

🩺HCPs play a critical role in the fight against cervical cancer. Empower your patients with resources about testing for prevention & early detection. 🔗Learn more during #CervicalCancerAwarenessMonth:

💙 Giving back is at the heart of @Amgen! In December, our team joined @LLSusa to assemble over 100 pediatric kits to bring comfort & smiles to kids with blood cancer at local children's hospitals. ✨ Proud to cap off another incredible year of collaboration with LLS!

📣#HCPs: Discover a new 🎯targeted option for metastatic colorectal cancer. 🔗Learn more:

NEWS: @Amgen’s biomarker-driven combination therapy for adult patients with chemorefractory KRAS G12C-mutated #mCRC received @US_FDA approval. Read more ⬇️

🧬B-cell-ALL treatment update: @GoHealio explains the critical impact of @Amgen’s recently approved BiTE® immunotherapy for frontline, consolidation phase care. 🔗Learn more: #AmgenSponsored

🚀In 2024, @Amgen took innovation to new heights. Hear from our oncology leaders about major advances in tough-to-treat cancers. ⬇️

🧬BiTE® cancer innovation: B-ALL & beyond 🧬 Discover how @Amgen aims to maximize the therapeutic potential of our BiTE® technology to tackle cancer frontiers. 🔗

A Decade of Progress & Hope in B-ALL✨ In celebration of 10 years since the first globally approved BiTE® therapy, Mary Ann reflects on how it affected her life, and Dr. Ashkan Emadi of @WVUCancer shares its impact in the field of oncology. Learn more:

🌟Celebrating 10 Years of BiTE® Innovation in B-ALL 🌟 Discover how @Amgen’s BiTE® science evolved care for people with B-cell precursor acute lymphoblastic leukemia (B-ALL). 🔗

Incredible energy at #ASH24 as new pediatric data on our BiTE® immunotherapy for B-cell precursor acute lymphoblastic leukemia (B-ALL) is shared. Moments like this fuel our drive to bring hope to kids and families. 💙

🌟New #ALL treatment advances bring us closer to a future where children like MJ can embrace hope & strength. 🔗Learn more: #ASH24

🩺News from #ASH24: Discover the study results that could impact care for a large number of children newly diagnosed with B-cell acute lymphoblastic leukemia (B-ALL) – the most common form of cancer in children.

At #ASH24, we look forward to discussing new pediatric patient data for @Amgen’s BiTE® immunotherapy added to chemotherapy in B-ALL. Discover how this approach could represent a new treatment standard for a large number of children with B-ALL. ⬇️ $AMGN